These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 15287825)

  • 1. Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries.
    Caro J; Salas M; Ward A; Getsios D; Migliaccio-Walle K; Garfield F
    Drugs Aging; 2004; 21(10):677-86. PubMed ID: 15287825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden.
    Garfield FB; Getsios D; Caro JJ; Wimo A; Winblad B
    Pharmacoeconomics; 2002; 20(9):629-37. PubMed ID: 12141890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK.
    Ward A; Caro JJ; Getsios D; Ishak K; O'Brien J; Bullock R;
    Int J Geriatr Psychiatry; 2003 Aug; 18(8):740-7. PubMed ID: 12891643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2002; 20(13):919-42. PubMed ID: 12381243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada.
    Getsios D; Caro JJ; Caro G; Ishak K;
    Neurology; 2001 Sep; 57(6):972-8. PubMed ID: 11571319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States.
    Migliaccio-Walle K; Getsios D; Caro JJ; Ishak KJ; O'Brien JA; Papadopoulos G;
    Clin Ther; 2003 Jun; 25(6):1806-25. PubMed ID: 12860500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands.
    Caro JJ; Salas M; Ward A; Getsios D; Mehnert A;
    Dement Geriatr Cogn Disord; 2002; 14(2):84-9. PubMed ID: 12145455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.
    Green C; Picot J; Loveman E; Takeda A; Kirby J; Clegg A
    Pharmacoeconomics; 2005; 23(12):1271-82. PubMed ID: 16336020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer's disease in Korea.
    Suh GH
    Value Health; 2009; 12 Suppl 3():S49-54. PubMed ID: 20586982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelling the clinical and economic implications of galantamine in the treatment of mild-to-moderate Alzheimer's disease in Germany.
    Guo S; Hernandez L; Wasiak R; Gaudig M
    J Med Econ; 2010; 13(4):641-54. PubMed ID: 20958114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cost-effectiveness of galantamine in a german context].
    Happich M; Schweikert B; Mühlbacher A
    Psychiatr Prax; 2005 Apr; 32(3):142-50. PubMed ID: 15818530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.
    Lamb HM; Goa KL
    Pharmacoeconomics; 2001; 19(3):303-18. PubMed ID: 11303418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.
    Jönsson L
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):77-86. PubMed ID: 16129384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: are the data relevant and available?
    Khang P; Weintraub N; Espinoza RT
    J Am Med Dir Assoc; 2004; 5(4):249-55. PubMed ID: 15228635
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time care.
    Caro JJ; Getsios D; Migliaccio-Walle K; Raggio G; Ward A;
    Neurology; 2001 Sep; 57(6):964-71. PubMed ID: 11571318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The costs of Alzheimer's disease and the value of effective therapies.
    Stefanacci RG
    Am J Manag Care; 2011 Nov; 17 Suppl 13():S356-62. PubMed ID: 22214393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic and clinical benefits of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population: a 52-week prospective study.
    Suh GH; Jung HY; Lee CU; Choi S;
    J Korean Med Sci; 2008 Feb; 23(1):10-7. PubMed ID: 18303192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.
    Small G; Erkinjuntti T; Kurz A; Lilienfeld S
    CNS Drugs; 2003; 17(12):905-14. PubMed ID: 12962529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial.
    Raskind MA; Peskind ER; Truyen L; Kershaw P; Damaraju CV
    Arch Neurol; 2004 Feb; 61(2):252-6. PubMed ID: 14967774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.